Retune Science Frontpage Image

TRR 295

Retuning dynamic motor network disorders using neuromodulation

Research insights to improve the therapy of brain disorders by the Transregional Collaborative Research Center TRR 295 ReTune, which is funded by the German Research Foundation (DFG).

Standard of care

Developing innovative neuromodulation therapies

Many neurological diseases are associated with movement disorders. Neuromodulation, a method that applies therapeutic electric currents or magnetic fields to the brain, has demonstrably helped restore motor deficits in movement-impaired patients. While deep brain stimulation (DBS) is considered the gold standard for treating Parkinson´s disease (PD) and various forms of tremor or dystonia, these therapies are not yet available for many other brain diseases.

Brain network dynamics and function

In the brain, approximately 86 billion nerve cells interact spatially and temporally to create a highly complex dynamic network whose exact functioning remains one of the great mysteries of brain research. One research focus of the TRR 295 ReTune is to understand the mechanisms and function of dynamic neuronal networks in health and disease in order to retune altered networks by invasive or non-invasive brain stimulation. The aim is to develop innovative neuromodulation systems that respond to specific demands, precisely target individual symptom cycles, and are activated only when disease symptoms occur.

Collaborative Research Centre TRR 295 ReTune

The Collaborative Research Centre TRR 295 ReTune consists of an interdisciplinary team of physicians, neuroscientists, and basic researchers from the Charité – Universitätsmedizin Berlin, Julius-Maximilians-Universität Würzburg, and seven other internationally renowned institutions in Düsseldorf, Potsdam, Leipzig, Rostock, Berlin, Würzburg, and Jerusalem. This multidisciplinary consortium is collaborating on various research projects, each addressing specific aspects of motor network disorders. The joint project is being funded with ten million euros by the German Research Foundation (DFG) for an initial period of four years starting in 2020.

Learn more about our TRR 295

“Our vision is to develop network-specific, yet minimally invasive neuromodulation methods for clinical practice to set new standards in the treatment of complex neurological movement disorders.”

Prof. Dr. Andrea Kühn, spokesperson of the TRR 295 ReTune and Head of Movement Disorders and Neuromodulation Unit at the Department of Neurology with Experimental Neurology, Charité – Universitätsmedizin Berlin.

News & Events

DGKN-Kongress 2026

DGKN-Kongress 2026

Feb 25-27, 2026 | Augsburg, Germany

The DGKN-Kongress 2026 takes place in Augsburg.
3rd Expert Summit on the Future of Deep Brain Stimulation

3rd Expert Summit on the Future of Deep Brain Stimulation

February 22-24, 2026 | Würzburg | Program

Keynote Speakers: Prof. Michael Fox | Dr. Helen Mayberg
ReTune Journal Club 2026 No. 1

ReTune Journal Club 2026 No. 1

Feb 3, 2026 | noon | Teams

presented by Begüm Devlet Kilickap & Lucia Poma
Stimulating Brains Jan 2026

Stimulating Brains Jan 2026

Jan 29, 2026 | noon | Zoom

with Andrew Pines and Nicola Cascella
Johannes Busch

Dr. Johannes Busch on the First Chronic Trial of Adaptive DBS

Jan 21, 2026

In this interview, Dr. Johannes Busch reflects on the first chronic clinical trial of adaptive deep brain stimulation in Parkinson’s disease and discusses its implications for personalized DBS therapy within the ReTune consortium.
Video Call on a Laptop

EO Community Meeting 2026 No. 1

Jan 13, 2026

Diversity and Discrimination Surveys in Science

All News & Events

Publications

Objective DBS program selection using smartphone-based kinematics.

Lange et al. 2026 Brain Stimul.

We appreciate the letter from our colleagues in response to our recently published article and thank them for their thoughtful comments.

Delphinidin modulates neuroinflammation and behavioral deficits in a Parkinson’s disease mouse model.

Grotemeyer et al. 2026 NPJ Parkinsons Dis.

We tested whether delphinidin, an anthocyanidin with reported inflammasome/NF-κB modulatory activity, alters neuroinflammation and nigrostriatal integrity in a progressive AAV1/2-A53T α-synuclein (hαSYN) mouse model.

Lesion Network Mapping of Acute Neurological Deficits and Its Prognostic Value After Ischemic Stroke.

Akdeniz et al. 2025 Neuroimage Clin.

Predicting functional recovery after ischemic stroke is vital for guiding clinical care. This study investigated whether lesion network mapping (LNM), a technique for modeling symptom-specific brain networks, can improve outcome prediction of functional recovery up to one-year post-stroke.

Reply to: Beta Coherence in Camptocormia: Marker of Compensation or Maladaptive Motor Memory?

Anjum et al. 2025 Mov Disord.

We appreciate the letter from Dr. Onder and colleagues in response to our recently published article and thank them for their thoughtful comments.

Predicting cognition after subthalamic Deep Brain Stimulation in Parkinson’s Disease.

Kübler-Weller et al. 2025 NPJ Parkinsons Dis.

This study takes into account the multifaceted etiology of cognition to estimate the cognitive outcome after deep brain stimulation (DBS) surgery in PD. Clinical, neuropsychological, perioperative, neuroimaging- and laboratory-based risk factors for cognitive dysfunction were prospectively assessed prior to surgery in 57 patients.

All Publications

https://sfb-retune.de/wp-content/uploads/2021/11/logo-charite.png
https://sfb-retune.de/wp-content/uploads/2021/11/logo-ukw.png
https://sfb-retune.de/wp-content/uploads/2021/11/logo-uni-duesseldorf.png
https://sfb-retune.de/wp-content/uploads/2021/11/logo-ltr.png
https://sfb-retune.de/wp-content/uploads/2021/11/logo-mpi.png
https://sfb-retune.de/wp-content/uploads/2021/11/logo-uni-potsdam.png
https://sfb-retune.de/wp-content/uploads/2021/11/logo-uni-rostock.png
https://sfb-retune.de/wp-content/uploads/2021/11/logo-uni-wuerzburg.png
https://sfb-retune.de/wp-content/uploads/2021/11/logo-bernstein.png